Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

(2013) O. E. Rahma et al.   ANNALS OF ONCOLOGY

Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy

(2013) E R Camp et al.   CANCER GENE THERAPY

Biodistribution and Pharmacokinetics of EGFR-Targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-Bearing Mice

(2013) Jing Xu et al.   MOLECULAR PHARMACEUTICS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer

(2009) S R Murugesan et al.   CANCER GENE THERAPY

Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine

(2009) José L. Arias et al.   JOURNAL OF DRUG TARGETING

Cytoplasmic functions of the tumour suppressor p53

(2009) Douglas R. Green et al.   NATURE

Antimetastatic Effects of Liposomal Gemcitabine and Empty Liposomes in an Orthotopic Mouse Model of Pancreatic Cancer

(2009) Ralph Graeser et al.   PANCREAS

Epidermal Growth Factor Receptor-Targeted Gelatin-Based Engineered Nanocarriers for DNA Delivery and Transfection in Human Pancreatic Cancer Cells

(2008) Padmaja Magadala et al.   AAPS Journal

Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent

(2008) C. R. Patra et al.   CANCER RESEARCH

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

(2008) Jean-Philippe Spano et al.   LANCET

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE